Alessandra Alessi
Vita-Salute San Raffaele University
CancerInternal medicineRadiologyOncologyStage (cooking)Standardized uptake valueClinical endpointPositron emission tomographyCystectomyChemotherapyCapecitabinePembrolizumabLymph nodeCabozantinibRegimenNuclear medicineIn patientFdg pet ctColorectal cancerBreast cancerMedicine
59Publications
11H-index
310Citations
Publications 58
Newest
#1Anna GuidettiH-Index: 16
#2Anna DoderoH-Index: 21
Last. Alessandra AlessiH-Index: 11
view all 0 authors...
Source
Source
#1Laura Marandino (University of Milan)H-Index: 10
#2Daniele Raggi (University of Milan)H-Index: 19
Last. Andrea Necchi (UniSR: Vita-Salute San Raffaele University)H-Index: 13
view all 11 authors...
Abstract Background : Durvalumab and cabozantinib have shown single-agent activity in patients with metastatic urothelial carcinoma (UC). ARCADIA is a phase 2 study evaluating their combination in patients with platinum-treated, advanced UC (NCT03824691). Herein we report the results of the planned interim safety analysis and the preliminary activity. Methods : Patients with an ECOG performance status 0-1, UC and non-UC histology, failure of a maximum of 2 regimens received cabozantinib 40 mg da...
Source
Abstract Background Data regarding the role of positron emission tomography/computed tomography (PET/CT) to stage lymph nodes in patients receiving neoadjuvant immunotherapy before radical cystectomy are lacking. The aim of this study is to evaluate the role of PET/CT to predict the pathologic lymph node involvement (LNI) in patients with MIBC receiving neoadjuvant pembrolizumab within the PURE-01 trial (NCT02736266). Material and methods Three courses of pembrolizumab were administered before r...
1 CitationsSource
Introduction Both DURVA and CABO, an inhibitor of MET, AXL, and VEGFR, have shown single-agent activity in pts with UC. ARCADIA is a phase 2 study evaluating the combination of CABO with DURVA in pts with advanced UC or non-UC histology (NCT03824691). Herein we report the results of the interim safety analysis and the preliminary activity. Methods Pts receive CABO 40 mg daily, orally, and are administered DURVA 1500 mg, intravenously, q28 days, until disease progression (PD, by RECIST 1.1) or on...
Source
#1Laura MarandinoH-Index: 10
#2Antonella CapozzaH-Index: 1
Last. Andrea NecchiH-Index: 35
view all 20 authors...
Abstract Background Data regarding the incidence and prognostic impact of immune-related imaging changes, assessed by 18[F] fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) scan, in patients receiving immune-checkpoint inhibitors (ICIs) are lacking. We relied on the population of patients enrolled in the PURE-01 study to evaluate such changes. Objective To evaluate the role of PET/CT to visualize the immune-related adverse events (irAEs) following pembrolizumab....
Source
#2Daniele RaggiH-Index: 19
Last. Andrea Necchi (University of Milan)H-Index: 35
view all 14 authors...
Background Pembrolizumab is a new standard of care for patients with platinum-treated, metastatic urothelial carcinoma (UC). Nab-paclitaxel is active in advanced UC. In the PEANUT study ( NCT03464734 ) we investigated their combination in advanced UC. Patients and methods PEANUT was an open-label, single-arm, phase II trial that included patients who had failed one or two chemotherapy regimens, including platinum chemotherapy. Biomarker analyses focused on programmed cell-death ligand-1 combined...
2 CitationsSource
#2Alessandra AlessiH-Index: 11
Last. Ettore SeregniH-Index: 48
view all 12 authors...
Source
#1Laura MarandinoH-Index: 10
#2Daniele RaggiH-Index: 19
Last. Andrea Necchi (University of Milan)H-Index: 35
view all 9 authors...
Source
#1Daniele RaggiH-Index: 19
#2Marco Bandini (UniSR: Vita-Salute San Raffaele University)H-Index: 24
Last. Andrea NecchiH-Index: 35
view all 11 authors...
Abstract Background Patients with advanced seminoma have an exceedingly favorable prognosis. Studies aimed to reduce the total treatment burden and side effects in well-defined, very good prognosis patients are warranted. Patients and methods In a prospective observational study, patients with advanced-stage seminoma were treated with bleomycin, etoposide and cisplatin (BEP) or EP according to guidelines. [18F]fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) examinati...
1 CitationsSource